• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Enliven Therapeutics, Inc. - Common Stock (NQ: ELVN )

    22.69 -0.24 (-1.05%)
    Streaming Delayed Price Updated: 3:47 PM EDT, Aug 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Enliven Therapeutics, Inc. - Common Stock

    ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024
    ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024
    ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
    Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising safety and efficacy data. 
    Via Benzinga
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
    Via Benzinga
    Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
    U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
    Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho... 
    Via Benzinga
    Wall Street Mixed As Tech Stocks Fall, Fed Meeting Begins
    Stocks are scattered midday Tuesday, as investors digest the semiconductor sector's pullback that's being led by the shares of Nvidia. 
    Via Talk Markets
    Topics Economy
    Exposures Interest Rates
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. 
    Via Benzinga
    National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023
    ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    7 A-Rated Biotech Stocks for Your August Buy List
    Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. 
    Via InvestorPlace
    Bears Reload On Mobileye After Sharp Gains In Stock Price
    Short interest on Mobileye Global fell from 23.9% to 21.2% in the week following the company’s Q1 results and FY23 guidance cut on April 27. However, Mobileye shares are up 31% from those lows over the... 
    Via Talk Markets
    Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
    Via Benzinga
    7 Biotech Stocks Sitting in the Sweet Spot
    Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable. 
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.